Stille

Stille FCF Growth

The Year-over-Year Free Cash Flow Growth of Stille (STIL.ST) as of Oct 24, 2026 is -73.90 %. In the previous year, Year-over-Year Free Cash Flow Growth was 143.04 % — a change of -151.66% (lower).

FCF Growth

-73.90 %

YoY

-151.66%

Last updated:

Year-over-Year Free Cash Flow Growth of Stille is 2025 -73.90 % . Year-over-Year Free Cash Flow Growth of Stille was 2024 143.04 % . It decreases by -151.66% lower compared to the previous year.

The Stille FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2018
-47.91 SEK
Jan 1, 2019
99.68 SEK
Jan 1, 2020
-116.10 SEK
Jan 1, 2021
-306.65 SEK
Jan 1, 2022
303.46 SEK
Jan 1, 2023
2.01 SEK
Jan 1, 2024
143.04 SEK
Jan 1, 2025
-73.90 SEK
The Stille FCF Growth history
YEARFCF GrowthYoY
-73.90 %-151.66%
143.04 %+7,020.50%
2.01 %-99.34%
303.46 %-198.96%
-306.65 %+164.12%
-116.10 %-216.48%
99.68 %-308.04%
-47.91 %+1,228.84%
-3.61 %-103.93%
91.67 %-73.38%
344.32 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Stille Stock analysis

What does Stille do? Stille AB generates revenue by developing and selling medical equipment through two distinct business lines. The Surgery business area focuses on handcrafted, forged surgical instruments for open surgery, particularly in cardiovascular, reconstructive, and aesthetic plastic surgery. This segment produces essential tools such as scissors, forceps, artery forceps, needle holders, and clamps for medical professionals requiring precision instruments. The second revenue stream comes from the Patient Positioning area, which manufactures specialized procedure-specific tables. These devices are designed for cardiovascular surgery as well as gynecology, urology, and urodynamic examinations. By offering tailored positioning solutions for these specific medical fields, the company supports clinical procedures that require precise patient alignment. The company's operational structure includes wholly owned subsidiaries Stille Surgical Inc. and Stille Incentive AB, which support its manufacturing and distribution efforts. In 2013, the company adjusted its portfolio by selling its Sonesta business unit to ADDvise Lab Solutions publ AB, allowing it to focus on its core surgical and positioning equipment offerings. Stille is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Stille stock

Year-over-Year Free Cash Flow Growth of Stille is -73.90 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Stille since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Stille historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Stille

All Key Metrics — Stille